Bangkok Genomics Innovation PCL (BKK:BKGI) Debt-to-Equity : 0.05 (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Bangkok Genomics Innovation PCL Debt-to-Equity?

Bangkok Genomics Innovation PCL's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ฿4.35 Mil. Bangkok Genomics Innovation PCL's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ฿18.32 Mil. Bangkok Genomics Innovation PCL's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ฿496.69 Mil. Bangkok Genomics Innovation PCL's debt to equity for the quarter that ended in Mar. 2024 was 0.05.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bangkok Genomics Innovation PCL's Debt-to-Equity or its related term are showing as below:

BKK:BKGI' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.11 Max: 0.3
Current: 0.05

During the past 5 years, the highest Debt-to-Equity Ratio of Bangkok Genomics Innovation PCL was 0.30. The lowest was 0.05. And the median was 0.11.

BKK:BKGI's Debt-to-Equity is ranked better than
81.87% of 193 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs BKK:BKGI: 0.05

Bangkok Genomics Innovation PCL Debt-to-Equity Historical Data

The historical data trend for Bangkok Genomics Innovation PCL's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bangkok Genomics Innovation PCL Debt-to-Equity Chart

Bangkok Genomics Innovation PCL Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.58

0.30

0.07

0.13

0.10

Bangkok Genomics Innovation PCL Quarterly Data
	Dec20	Dec21	Mar22	Dec22	Mar23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial			N/A	0.13	0.13	0.10	0.05

Competitive Comparison of Bangkok Genomics Innovation PCL's Debt-to-Equity

For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bangkok Genomics Innovation PCL's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bangkok Genomics Innovation PCL's Debt-to-Equity falls into.

Bangkok Genomics Innovation PCL Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bangkok Genomics Innovation PCL's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.285	+	19.435)	/	235.819
	=	0.10

Bangkok Genomics Innovation PCL's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.351	+	18.322)	/	496.692
	=	0.05

Bangkok Genomics Innovation PCL (BKK:BKGI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Bangkok Genomics Innovation PCL Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Bangkok Genomics Innovation PCL's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bangkok Genomics Innovation PCL (BKK:BKGI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Bangkok Genomics Innovation PCL (BKK:BKGI) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

3689 Rama 4 Road, Phra Khanong Subdistrict, Khlong Toei Subdistrict, Bangkok, THA, 10110

Website

https://www.bangkokgenomics.com

Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products).